Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial
Pedro A Lemos, Bruno Moulin, Marco A Perin, Ludmilla A R R Oliveira, J Airton Arruda, Valter C Lima, Antonio A G Lima, Paulo R A Caramori, Cesar R Medeiros, Mauricio R Barbosa, Fabio S Brito Jr, Expedito E Ribeiro, Pedro A Lemos, Bruno Moulin, Marco A Perin, Ludmilla A R R Oliveira, J Airton Arruda, Valter C Lima, Antonio A G Lima, Paulo R A Caramori, Cesar R Medeiros, Mauricio R Barbosa, Fabio S Brito Jr, Expedito E Ribeiro
Abstract
Aims: The long-term clinical performance of drug-eluting stents (DES) coated with biodegradable polymers is poorly known.
Methods and results: A total of 274 coronary patients were randomly allocated to paclitaxel-eluting stents, sirolimus-eluting stents, or bare metal stents (2:2:1 ratio). The two DES used the same biodegradable polymers and were identical except for the drug. At three years, the pooled DES population had similar rates of cardiac death or myocardial infarction (9.0% vs. 7.1; p=0.6), but lower risk of repeat interventions (10.0% vs. 29.9%; p<0.01) than controls with bare stents. The cumulative 3-year incidence of definite or probable stent thrombosis in the pooled DES group was 2.3% (first year: 1.8%; second year: 0.4%; third year: zero). There were no significant differences in outcomes between paclitaxel- and sirolimus-eluting stents.
Conclusions: The biodegradable-polymer coated DES releasing either paclitaxel or sirolimus were effective in reducing the 3-year rate of re-interventions.
Source: PubMed